News from Thursday, August 28, 2025
Articles
Real-World Data Show Dapagliflozin, Empagliflozin Are Safe Options for Diabetes
(8/27, Ashley Gallagher, Drug Topics) reports “...‘Both dapagliflozin and empagliflozin demonstrated statistically comparable cardiorenal benefits and safety outcomes, with consistent results across various sensitivity analyses and prespecified subgroups,’ the authors said. ‘In the sensitivity analysis focusing on unstable prior ACEI/ARB exposure, empagliflozin use was associated with an increased risk of all-cause death compared to dapagliflozin.’” Full
Journals
Comparative Effectiveness of Remote Perioperative Telemonitoring in Cancer Surgery: A Randomized Trial
Virginia Sun, et al.
August 28, 2025, NPJ Digital Medicine
Patient-Reported Outcomes (PROs) Now and into the Future: Multi-Stakeholder Perspectives on Optimizing PRO Evidence Use in Decision-Making across the US Healthcare Continuum
Sharan Randhawa, MSc, et al.
August 28, 2025, Value in Health
Comparative Effectiveness and Prescribing Patterns of Dapagliflozin vs Empagliflozin in Type 2 Diabetes Patients: A Target Trial Emulation
I-Ning Yang, et al.
October 2025, Diabetes Research and Clinical Practice